Filing summary
Entity and period: The supplied filing is Prestige Brands Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2012, filed May 17, 2012. This differs from the requested company name, Prestige Consumer Healthcare Inc.; verify the intended issuer. The “2011 Q4” metadata does not match the filing period. Fiscal 2012 fourth-quarter figures are noted below where relevant.
Business context and reporting period
The company markets and distributes OTC healthcare and household cleaning products, primarily in North America, using outsourced manufacturing. OTC healthcare represented 78.2% of fiscal 2012 revenue, up from 69.7%; household cleaning represented 21.8%, down from 30.3%.
Growth was driven substantially by acquisitions: 15 GSK brands acquired in January 2012 for $615 million and Debrox and Gly-Oxide acquired in March for $45 million, alongside the full-year contribution from the 2011 Blacksmith and Dramamine acquisitions. The GSK brands acquired in January contributed $30.4 million of revenue and a $2.8 million net loss for the two months included in fiscal 2012.
Financial performance
| Metric | FY2012 | FY2011 | Change |
|---|---|---|---|
| Total revenue | $441.1 million | $336.5 million | +31.1% |
| Gross profit / margin | $227.4 million / 51.6% | $170.9 million / 50.8% | +33.1%; margin +0.8 percentage points |
| Operating income / margin | $102.8 million / 23.3% | $76.1 million / 22.6% | +35.1% |
| Net income | $37.2 million | $29.2 million | +27.3% |
| Diluted EPS | $0.73 | $0.58 | +$0.15 |
| Cash from operations | $67.5 million | $86.7 million | -$19.2 million |
| Capital expenditures | $0.6 million | $0.7 million | -$0.05 million |
Net interest expense rose to $41.3 million from $27.3 million, mainly because of higher acquisition-related debt. The year included a $5.1 million gain on a legal settlement and a $5.4 million loss on extinguishment of debt; both affected comparisons with recurring earnings.
At March 31, 2012, cash was $19.0 million, current assets $147.0 million, and current liabilities $63.9 million (current ratio about 2.3x). Debt principal was $1.135 billion, versus $492 million a year earlier; net debt was approximately $1.116 billion. The company reported $50 million of unused capacity on its asset-based revolver. Total assets were $1.758 billion, including $1.574 billion of goodwill and intangible assets; stockholders’ equity was $402.7 million.
Operating cash flow fell as working capital shifted from a $31.4 million inflow in FY2011 to a $5.4 million outflow in FY2012, notably reflecting higher receivables after the GSK acquisition. Acquisition spending drove investing cash outflow of $662.2 million; financing activities provided $600.4 million.
Changes versus the prior year
- OTC healthcare revenue increased 47.1% to $345.0 million, reflecting acquisitions and growth in some legacy brands. Household cleaning revenue declined 5.7% to $96.1 million; Comet softness and promotional discounting weighed on the segment’s gross margin, which fell to 26.6% from 33.4%.
- Consolidated gross margin improved as the revenue mix shifted toward higher-margin OTC healthcare products and acquisition-related inventory step-up charges fell to $1.8 million from $7.3 million.
- General and administrative expense increased to $56.7 million from $42.0 million, including $13.8 million of GSK acquisition costs and $1.7 million of costs defending against an unsolicited offer.
- Debt rose sharply to fund the GSK transaction. The company issued $250 million of 8.125% notes due 2020 and entered into a $660 million term loan facility; $635 million remained outstanding under the term loan at year-end.
Outlook, risks, and unusual matters
- No numerical revenue or earnings guidance is provided. Management expected advertising and promotion spending on the acquired GSK core brands in FY2013 to exceed spending on legacy core OTC brands. The GSK transition services agreement cost about $2.5 million per month and was scheduled to run through June 30, 2012.
- Management said it expected to meet debt covenants in the ensuing year; the company was compliant at year-end. Covenants include leverage, interest coverage, and fixed-charge tests. A one-percentage-point increase in rates on variable-rate debt was estimated to reduce annual pretax earnings and cash flow by about $6.4 million.
- Key exposures include substantial leverage and cross-default provisions, dependence on Walmart (18.9% of gross revenue) and a small number of large customers, reliance on third-party manufacturers and one primary U.S. distribution center, competitive and private-label pressure, input-cost inflation, regulation and product recalls, and the high concentration of assets in goodwill and intangible assets. A supplier inherited in the GSK acquisition had filed for bankruptcy; the company was seeking an alternative source for an internationally sold brand.
- Genomma Lab’s unsolicited, non-binding $16.60-per-share acquisition proposal was rejected as inadequate; Genomma withdrew its proposal and board slate in May 2012. The company adopted a stockholder rights plan in February 2012. No impairment charge was recorded in fiscal 2012, and the auditor and management reported effective internal control over financial reporting.
- Fiscal 2012 Q4 revenue was $134.0 million and operating income was $22.6 million. The quarter reported a $15,000 net loss, reflecting $16.3 million of net interest expense and the $5.4 million debt-extinguishment loss, partly offset by the settlement gain recorded earlier in the year.
Investor verification priorities
- Confirm the correct issuer and reporting period; the filing is for Prestige Brands Holdings, Inc. and fiscal 2012, not a standalone 2011 Q4 report.
- Assess whether GSK brands can be integrated, grow organically, and support the purchase-price valuations; note that the purchase-price allocation was preliminary and the GSK brands’ included-period results showed a net loss.
- Review debt amortization, floating-rate exposure, covenant headroom, and the company’s capacity to reduce leverage while funding brand support.
- Track operating cash flow and working-capital needs, particularly receivables and the transition from GSK’s services to the company’s own processes.
- Monitor household cleaning margins, customer concentration, manufacturer continuity, and any product-safety, regulatory, litigation, or impairment developments.